AVAdeno Study: An Observational Study of First-Line Avastin (Bevacizumab) in Patients With Adenocarcinoma of the Lung
Completed
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- Registration Number
- NCT01827852
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
This prospective observational study will evaluate the efficacy and safety of first-line Avastin (bevacizumab) in combination with platinum-based chemotherapy in different age groups (\<60, 60-69, 70-79, \>80 years) in patients with inoperable advanced, metastatic or recurrent adenocarcinoma non-small cell lung cancer. Patients will be followed for 18 months from the start of first-line therapy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1107
Inclusion Criteria
- Adult patients, >/= 18 years of age
- Histologically confirmed inoperable advanced, metastatic or recurrent pre-dominantly non-squamous adenocarcinoma non-small cell lung cancer
Exclusion Criteria
- Contraindications to Avastin treatment according to the Summary of Product Characteristics
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression-free survival in 4 different age groups (<60, 60-69, 70-79, >/=80 years) approximately 4.5 years
- Secondary Outcome Measures
Name Time Method Clinical/demographic patient characteristics at initiation of treatment approximately 4.5 years Concomitant anti-neoplastic therapy (dosage/duration) approximately 4.5 years Safety: Incidence of adverse events in 4 different age groups (<60, 60-69, 70-79, >/=80 years) approximately 4.5 years Avastin treatment schedule in routine clinical practice (dosage/duration) approximately 4 years Overall survival in 4 different age groups (<60, 60-69, 70-79, >/=80 years) approximately 4.5 years
Trial Locations
- Locations (1)
Universität Leipzig; Medizinische Klinik und Poliklinik I, Abteilung Pneumologie
🇩🇪Leipzig, Germany